Seegene Highlights the Need for Comprehensive Reproductive Tract Infection Testing Through 'Global Million Clinical Study'
Seegene, a global total solution provider in molecular diagnostics, announced on July 27 that it proposes the necessity of a comprehensive syndromic PCR-based reproductive tract infection (RTI1) test, which can simultaneously determine the presence of sexually transmitted infections (STI) and human papillomavirus (HPV).
Seegene plans to present the need for syndromic PCR-based comprehensive testing and outline its future strategies at the Association for Diagnostics & Laboratory Medicine (ADLM 2026), which will be held from July 28 to July 30 in Anaheim, California, USA.
As a result of independently analyzing approximately 60,000 cases of simultaneous HPV·STI3 test data generated over 3 years and 6 months (42 months) using Seegene's real-time test data analysis statistics platform STAgora™. Seegene
View original imageOn July 8, Seegene announced the 'Global Million Clinical Study (GMCS),' under which healthcare institutions around the world are accumulating real clinical data and, based on this, are validating the clinical value of tests for various diseases. This initiative has provided the scientific evidence for new global testing standards (Global New Standards).
HPV is known as the main causative virus of cervical cancer. High-risk genotypes, including HPV types 16 and 18, are particularly closely related to the development of cervical cancer, and the need for screening and follow-up testing may differ depending on the detected genotype. Therefore, identifying not only the presence of HPV infection but also the specific genotype detected is considered important clinical information.
STIs are caused by various pathogens, such as Chlamydia trachomatis and Neisseria gonorrhoeae, and present a wide range of symptoms, including abnormal discharge, dysuria, genital pain or itching, dyspareunia, lower abdominal pain, genital ulcers, vesicles, warts, and infertility. Because different pathogens can produce similar symptoms, it is difficult to identify the specific causative pathogen based on clinical presentation alone. In addition, asymptomatic infections are common and may be transmitted without being recognized.
Furthermore, recent research2 suggests that STIs and vaginal microbial imbalance may influence local cervical inflammation and the immune environment, which in turn could affect HPV infection or viral clearance. Therefore, a comprehensive clinical interpretation of the types of pathogens identified through HPV and STI test results, as well as the patient's infection history, is necessary.
According to Seegene's independent analysis of approximately 60,000 cases of simultaneous HPV and STI3 test data generated over 3 years and 6 months (42 months) using its real-time test data analysis and statistics platform STAgora™, STI pathogens were detected in 82% of cases with positive results for the 28 types of HPV, and HPV was present in 46% of STI-positive cases. Moreover, simultaneous detection was confirmed in 71% of cases where both HPV and STI were included in comprehensive positive test results.
These findings illustrate the utility of conducting STI testing alongside HPV screening. In particular, this approach has the potential for applications such as identifying asymptomatic STIs, evaluating co-infections in HPV-positive patients, and assessing reproductive health during preconception or infertility evaluations.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seegene plans to continue obtaining clinical results from comprehensive HPV·STI testing as part of the GMCS, and will statistically verify the clinical utility and applicability of this comprehensive test using the STAgora platform.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.